Compare LYV & RVMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LYV | RVMD |
|---|---|---|
| Founded | 2005 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.7B | 40.3B |
| IPO Year | 2005 | 2020 |
| Metric | LYV | RVMD |
|---|---|---|
| Price | $172.88 | $182.20 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 25 | 25 |
| Target Price | $202.63 | ★ $258.84 |
| AVG Volume (30 Days) | 1.4M | ★ 1.9M |
| Earning Date | 11-05-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $25,201,406,000.00 | N/A |
| Revenue This Year | $11.59 | N/A |
| Revenue Next Year | $9.27 | $526.64 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 8.83 | N/A |
| 52 Week Low | $125.34 | $56.66 |
| 52 Week High | $189.25 | $224.31 |
| Indicator | LYV | RVMD |
|---|---|---|
| Relative Strength Index (RSI) | 51.55 | 40.39 |
| Support Level | $171.00 | $177.62 |
| Resistance Level | $174.45 | $194.19 |
| Average True Range (ATR) | 3.58 | 9.96 |
| MACD | 0.56 | -0.52 |
| Stochastic Oscillator | 56.01 | 23.90 |
Live Nation is the largest live entertainment company in the world, serving as a concert promoter, venue operator, and ticketing platform. In addition, the firm generates revenue from sponsorships and advertising. With offices in 51 countries, Live Nation promotes concerts globally. It owned, operated, or had exclusive booking rights to more than 400 venues worldwide at the end of 2025, which the firm says makes it the second-largest operator of music venues globally. In 2025, Live Nation promoted nearly 55,000 events, drawing roughly 160 million fans. Ticketmaster is a dominant global ticketing service, selling nearly 650 million tickets in 2025.
Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.